Patents by Inventor George Doherty

George Doherty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,3,4,7-tetrahydro-2H-pyrrolo[3?,2?:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors
    Patent number: 11964990
    Abstract: The present invention provides for compounds of Formula (I) wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: April 23, 2024
    Assignee: AbbVie Inc.
    Inventors: George A. Doherty, Vikram Bhat, Andrew S. Judd, Andrew J. Souers
  • BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same
    Publication number: 20240058450
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: May 31, 2022
    Publication date: February 22, 2024
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 11897864
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Grant
    Filed: October 7, 2022
    Date of Patent: February 13, 2024
    Assignees: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20240043404
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: September 6, 2023
    Publication date: February 8, 2024
    Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
    Publication number: 20230399340
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: October 12, 2022
    Publication date: December 14, 2023
    Inventors: Wilfried Braje, George Doherty, Katja Jantos, Cheng Ji, Andrew Judd, Aaron Kunzer, Anthony Mastracchio, Xiaohong Song, Andrew Souers, Gerard Sullivan, Zhi-Fu Tao, Chunqiu Lai, Andreas Kling, Frauke Pohlki, Jesse Teske, Michael Wendt, Patrick Brady, Xilu Wang, Thomas Penning, Michael Michaelides
  • ANTI-C-MET ANTIBODY DRUG CONJUGATES
    Publication number: 20230372519
    Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.
    Type: Application
    Filed: March 9, 2023
    Publication date: November 23, 2023
    Applicant: AbbVie Inc.
    Inventors: Andrew C. Phillips, Regina M. Reilly, George A. Doherty, Cheng Ji, Milan Bruncko, Erwin R. Boghaert, Mark Anderson
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 11786519
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: October 17, 2023
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors
    Publication number: 20230234971
    Abstract: The present invention provides for compounds of Formula (I) wherein A, L, W, and R1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL, SLL, and/or ALL.
    Type: Application
    Filed: January 19, 2023
    Publication date: July 27, 2023
    Applicant: AbbVie Inc.
    Inventors: George A. Doherty, Vikram Bhat, Patrick Brady, Yujia Dai, Jianchun Gong, Andrew S. Judd, Andrew J. Souers, Yiyun Yu
  • Macrocyclic MCL-1 Inhibitors and Methods of Use
    Publication number: 20230183261
    Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: February 3, 2022
    Publication date: June 15, 2023
    Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning
  • APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20230143532
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: October 7, 2022
    Publication date: May 11, 2023
    Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • Anti-c-Met antibody drug conjugates
    Patent number: 11633497
    Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: April 25, 2023
    Assignee: AbbVie Inc.
    Inventors: Andrew C. Phillips, Regina M. Reilly, George A. Doherty, Cheng Ji, Milan Bruncko, Erwin R. Boghaert, Mark Anderson
  • ANTI-C-MET ANTIBODY DRUG CONJUGATES
    Publication number: 20220378935
    Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.
    Type: Application
    Filed: April 29, 2022
    Publication date: December 1, 2022
    Inventors: Andrew C. PHILLIPS, Regina M. REILLY, George A. DOHERTY, Cheng JI, Milan BRUNCKO, Erwin R. BOGHAERT, Mark ANDERSON
  • APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20220315555
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: November 3, 2021
    Publication date: October 6, 2022
    Applicants: AbbVie Inc., Genentech, Inc., The Walter and Eliza Hall Institute of Medical Research
    Inventors: Milan BRUNCKO, Hong DING, George A. DOHERTY, Steven W. ELMORE, Lisa A. HASVOLD, Laura HEXAMER, Aaron R. KUNZER, Xiaohong SONG, Andrew J. SOUERS, Gerard M. SULLIVAN, Zhi-Fu TAO, Gary T. WANG, Le WANG, Xilu WANG, Michael D. WENDT, Robert MANTEI, Todd M. HANSEN
  • MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
    Publication number: 20220259226
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: April 22, 2022
    Publication date: August 18, 2022
    Inventors: Wilfried Braje, George Doherty, Katja Jantos, Cheng Ji, Andrew Judd, Aaron Kunzer, Anthony Mastracchio, Xiaohong Song, Andrew Souers, Gerard Sullivan, Zhi-Fu Tao, Chunqiu Lai, Jesse Teske, Michael Wendt, Patrick Brady, Xilu Wang, Thomas Penning, Yujia Dai, Jane Gong, Roberto Risi, Yiyun Yu, Guidong Zhu
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20210346369
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 1, 2020
    Publication date: November 11, 2021
    Applicant: AbbVie Inc.
    Inventors: Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
  • MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
    Publication number: 20210292339
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: October 23, 2020
    Publication date: September 23, 2021
    Inventors: Wilfried BRAJE, George DOHERTY, Katja JANTOS, Cheng JI, Andrew JUDD, Aaron KUNZER, Anthony MASTRACCHIO, Xiaohong SONG, Andrew SOUERS, Gerard SULLIVAN, Zhi-Fu TAO, Chunqiu LAI, Jesse TESKE, Michael WENDT, Patrick BRADY, Xilu WANG, Thomas PENNING, Yujia DAI, Jane GONG, Roberto RISI, Yiyun YU, Guidong ZHU
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20210228565
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: September 16, 2020
    Publication date: July 29, 2021
    Applicant: AbbVie Inc.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20210221789
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
    Type: Application
    Filed: August 27, 2020
    Publication date: July 22, 2021
    Inventors: Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
  • APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
    Publication number: 20200345717
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 18, 2019
    Publication date: November 5, 2020
    Applicant: AbbVie Inc.
    Inventors: Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
  • Macrocyclic MCL-1 Inhibitors and Methods of Use
    Publication number: 20200325153
    Abstract: The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
    Type: Application
    Filed: May 11, 2020
    Publication date: October 15, 2020
    Inventors: Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Jesse A. Teske, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Katja Jantos, Wilfried Braje, Andreas Kling, Frauke Pohlki, Thomas D. Penning